Alessandra Michelucci, Flavia Manzo Margiotta, Salvatore Panduri, Annalisa Tonini, Marco Romanelli, Riccardo Morganti, Agata Janowska, Valentina Dini
Issues - Aprile 2022
Alessandra Michelucci, Flavia Manzo Margiotta, Salvatore Panduri, Annalisa Tonini, Marco Romanelli, Riccardo Morganti, Agata Janowska, Valentina Dini
Alison Havelin, Philip Hampton
Telemedicine and e-health in the management of psoriasis: improving patient outcomes – A narrative review
Psoriasis (Auckl). 2022 Mar 16;12:15-24Åshild Ø Solvin, Konika Chawla, Lene C Olsen, Siv Anita Hegre, Kjersti Danielsen, Marita Jenssen, Anne-Sofie Furberg, Marit Saunes, Kristian Hveem, Pål Saetrom, Mari Løset
MicroRNA profiling of psoriatic skin identifies 11 miRNAs associated with disease severity
Exp Dermatol. 2022 Apr;31(4):535-547Noha Mohammed Dawoud, Maha Bedair El Badawy, Hala Subhi Al Eid, Moataz M Abdel Fattah
Risankizumab effectiveness and safety in psoriasis patients who failed other biologics: Real-life case series
Indian J Dermatol Venereol Leprol. Mar-Apr 2022;88(2):235-240Maartje R van Acht, Juul MPA van den Reek, Elke MGJ de Jong, Marieke MB Seyger
The effect of lifestyle changes on disease severity and quality of life in patients with plaque psoriasis: A narrative review
Psoriasis (Auckl). 2022;12:35-51I van Ee, E Deprez, A Egeberg, M Augustin, C Conrad, V Corazza, L Donati, J Lambert, R Lăpădatu, A Meyer, C Paul, R Penzer-Hick, K Stephen, J van der Zon, A Bewley
Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians
J Eur Acad Dermatol Venereol. 2022 Mar;36(3):403-412Andrew Blauvelt, Nianwen Shi, Najwa Somani, Russel Burge, Baojin Zhu, Terri L Ridenour, Carolyn R Lew, Nicole M Zimmerman, Bilal Atiya, Mwangi J Murage
Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings
J Am Acad Dermatol. 2022 Mar;86(3):581-58Jerry Bagel, Elise Nelson
Adjunctive Use of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam in patients with psoriasis treated with ixekizumab
J Drugs Dermatol. 2022 Mar 1;21(3):235-24R Rivera-Diaz, M Llamas-Velasco, G Carretero, D Ruíz-Genao, I Belinchón, J Riera-Monroig, P de la Cueva, M Ferrán, M de Vega, I García-Doval
Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) breastfeed less when compared with general population
J Eur Acad Dermatol Venereol. 2022 Mar;36(3):e205-e20F Bardazzi, G Clarizio, A Marani, V Tengattini, L Sacchelli
The burden of psoriasis on patient’s caregivers
J Eur Acad Dermatol Venereol. 2022 Mar;36(3):e238-e23Charles N Ellis, Stephen J Neville, Mohamed Sayyouh, James T Elder, Rajan P Nair, Johann E Gudjonsson, Tianwen Ma, Ella A Kazerooni, Melvyn Rubenfire, Prachi P Agarwal
Epicardial adipose tissue volume is greater in men with severe psoriasis, implying an increased cardiovascular disease risk: A cross-sectional study
J Am Acad Dermatol. 2022 Mar;86(3):535-54Nikolai Loft, Thao Thi Nguyen, Lars Erik Kristensen, Jacob P Thyssen, Alexander Egeberg
Disease burden, symptoms, and use of analgesics in patients with psoriasis with or without psoriatic arthritis: A cross-sectional study
J Am Acad Dermatol. 2022 Mar;86(3):590-59Takahiro Suzuki, Taisuke Ito, Amos Gilhar, Yoshiki Tokura, Kristian Reich, Ralf Paus